Company Announcement / Press release Archives - Page 2 of 15

Interim Report First Quarter 2023

January–March 2023, Group Net sales amounted to SEK 0 thousand (0) Loss before tax amounted to SEK -34,827 thousand (-18,934) Earnings per share before dilution amounted to SEK -1.54 (-0.92) Cash flow from operating activities amounted to SEK -45,535 thousand (-27,613) Cash flow from investing activities amounted to SEK -14,650 thousand (-47,541) Significant events during […]

Notice of extraordinary general meeting in Xspray Pharma AB (publ)

The shareholders of Xspray Pharma AB (publ), Reg. No. 556649-3671, (”Xspray Pharma”) are summoned to an extraordinary general meeting on Thursday 25 May 2023 at 13.00 CEST at Advokatfirman Vinge’s office on Smålandsgatan 20 in Stockholm. Registration for the extraordinary general meeting starts at 12.30 CEST. The shareholders may exercise their voting rights at the […]

Xspray announces a rights issue of units of approximately SEK 300 million ahead of Dasynoc product launch

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR […]

Xspray Pharma receives expected partial decision in patent case regarding matter of law

A United States district court has decided to deny the “motion to dismiss” from Xspray Pharma in the company's ongoing patent dispute. The ruling means that the counter party is allowed to pursue the case further. The dispute concerns a patented crystalline substance that has no presence in Xspray Pharma's product candidate. Xspray Pharma therefore […]

Notice of annual general meeting of Xspray Pharma AB (publ)

The shareholders of Xspray Pharma AB (publ), Reg. No. 556649-3671, (”Xspray Pharma”) are summoned to the annual general meeting on Tuesday 16 May 2023 at 10.00 CEST at Advokatfirman Vinge’s office on Smålandsgatan 20 in Stockholm. Registration starts at 9.30 CEST. The shareholders may exercise their voting rights at the annual general meeting by attending […]

Xspray Pharma publishes its Annual Report 2022

Xspray Pharma AB (publ) today publishes its Annual Report for the financial year 2022. The Annual Report is attached to this press release and available on the company’s website: https://xspraypharma.com/investors/financial-reports/ An extract from the CEO-letter from Per Andersson, CEO of Xspray Pharma: “We made important progress during 2022 in completing our first product intended for launch […]

Board member in Xspray Pharma acquires shares from the CEO

Anders Bladh, board member of Xspray Pharma, through his company Ribbskottet AB, has acquired 30,000 shares in Xspray Pharma from the CEO Per Andersson. Xspray Pharma's CEO Per Andersson has sold 30,000 shares in Xspray Pharma, on March 13, 2023, to Board Member of Xspray Pharma, Anders Bladh via his company Ribbskottet AB. The transaction […]

Xspray Pharma Partners with EVERSANA for the U.S. Launch and Commercialization of its Lead Product, Dasynoc (XS004) for the Treatment of Chronic Myeloid Leukemia (CML) and Acute Lymphatic Leukemia (ALL)

Xspray Pharma AB, (NASDAQ Stockholm: XSPRAY) has signed an agreement with EVERSANA® to support the U.S. launch and commercialization of the company’s first innovative cancer therapy Dasynoc for the treatment of chronic myeloid leukemia (CML) and acute lymphatic leukemia (ALL). While maintaining financial and strategic control, Xspray Pharma will grant EVERSANA exclusive commercialization access to […]

Interim Report Fourth Quarter 2022

October–December 2022, Group Net sales amounted to SEK 0 thousand (0) Loss before tax amounted to SEK -55,220 thousand (-51,944) Earnings per share before dilution amounted to -2.48 SEK (-2.62) Cash flow from operating activities amounted to SEK -35,003 thousand (-10,280) Cash flow from investing activities amounted to SEK -29,481 thousand (-33,691) January–December 2022, Group […]

Xspray presents novel scientific data for XS004 in the Chronic Myeloid Leukemia (CML) session at the 2022 Meeting of the American Society of Hematology

Xspray Pharma AB (NASDAQ Stockholm: XSPRAY), a biopharmaceutical company focused on developing high performing, amorphous forms of tyrosine kinase inhibitors (TKIs), has presented two posters examining the pharmacokinetics of XS004-dasatinib in healthy volunteers at the 64th Annual Meeting of the American Society of Hematology (ASH), December 10-13 in New Orleans, USA. “The treatment of CML […]